Clinical trial
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating…
NCT00121303 · Stichting Hemato-Oncologie voor Volwassenen Nederland, Other · Completed
Key facts
| NCT number | NCT00121303 |
|---|---|
| Title | Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes |
| Official title | Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) |
| Lead sponsor | Stichting Hemato-Oncologie voor Volwassenen Nederland, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | cytarabine, daunorubicin hydrochloride, gemtuzumab ozogamicin |
| Enrollment | 600 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jun 1, 2016 |
| First posted | Jul 21, 2005 |
| Last update posted | Sep 20, 2016 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: